THE Therapeutic Goods Administration has granted approval for Seqirus's Ryaltris (olopatadine hydrochloride and mometasone furoate) combination nasal spray, for the treatment of allergic rhinitis and rhino-conjunctivitis in children aged six years and older.
The treatment is now available as a private script for patients with unmet needs.
The above article was sent to subscribers in Pharmacy Daily's issue from 23 Mar 22
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 Mar 22
